课题基金 / 基金详情

IMMUNOCHEMICAL CHARACTERIZATION OF HUMAN PLASMA LIPOPROT

IMMUNOCHEMICAL CHARACTERIZATION OF HUMAN PLASMA LIPOPROT
人血浆 LIPOPROT 的免疫化学特性
批准号:
3343676
负责人:
SIMON J MAO
金额:
$11.98万
依托单位国家:
美国
项目类别:
财政年份:
1983
资助国家:
美国
项目状态:
已结题
起止时间:
1983-09-01 至 1988-03-31

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Knowledge of human apolipoprotein structure has contributed to the understanding of normal and abnormal lipid transport and metabolism. Recent studies have shown that apolipoprotein (apo) A-1 and B are closely associated with the presence of atherosclerosis. It is known that a structural defect of apo A-1 due to amino acid substitutions will eventually lead to the development of coronary artery disease (CAD). However, it is not clear at the present time whether structural defects in apo-B can give rise to clinically significant disease. This proposal is designed to utilize a number of immunochemical tools to probe the orientation and structure of apolipoproteins and of lipoprotein particles. The definition of the antigenic sites of apolipoproteins will permit the use of blocking antibodies to map the physiologically active sites on the apolipoprotein molecule. It will also permit the probing of possible structural differences in patients with CAD. Short term goals of the present studies will be to: a) map out the antigenic structure of apo A-I; b) determine the differences in the immunochemical properties of apo B between the patients with and without CAD. Long term goals will be to: a) establish the apolipoprotein and lipid relationship in patients with coronary artery disease; b) sort out the various apo B components with monoclonal antibodies and to delineate their possible atherogenic role; c) provide the antigenic structure and immunochemical properties of apolipoproteins and lipoproteins; and d) utilize monoclonal antibodies as probes to study the structure and function of lipoproteins.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
  • 批准号:
    2022J011295
  • 项目类别:
    省市级项目
  • 资助金额:
    10.0万元
  • 批准年份:
    2022
  • 负责人:
    王亚伟
  • 依托单位:
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究